Establishment and application of drug use evaluation criteria of recombinant human prourokinase
10.12173/j.issn.1005-0698.202312031
- VernacularTitle:重组人尿激酶原药物利用评价标准的建立与应用
- Author:
Zhihe ZHUANG
1
;
Qin QIN
;
Huiya CAI
;
Tianyu MA
;
Runqiu WANG
;
Qian XIANG
;
Jinhua ZHANG
Author Information
1. 锡林郭勒盟中心医院药学部(内蒙古锡林郭勒 026000)
- Keywords:
Recombinant human prourokinase;
Drug use evaluation;
Standard rules;
Rational drug use;
Adverse drug reaction
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(4):371-380
- CountryChina
- Language:Chinese
-
Abstract:
Objective To establish the drug use evaluation(DUE)criteria of recombinant human prourokinase(rhPro-UK),and to provide reference for the rational clinical application of rhPro-UK.Methods Based on the drug instructions of rhPro-UK,DUE standard rules were established by referring to relevant guidelines,expert consensus,authoritative literature and expert consultation.The medical records of hospitalized patients treated with rhPro-UK from January 2019 to May 2022 in Xilin Gol League Central Hospital were evaluated by retrospective investigation.The effectiveness of rhPro-UK was evaluated based on clinical outcome,and its safety was evaluated based on the incidence and severity of adverse reactions.Results A total of 230 cases were included,and 4 cases fully met the evaluation criteria(medication indication,medication process,medication results),accounting for 1.74％.There were 226 patients(98.26％)with irrational drug use,mainly manifested in two aspects of drug indication and drug process(administration mode and dosage).Treatment was effective in 221 patients,with an overall effective rate of 96.09％;139 patients experienced adverse reactions,with an incidence rate of 60.43％.Conclusion The clinical use of rhPro-UK in our hospital is irrational in the indication of medication and the process of medication,and the establishment of the DUE standard rules of rhPro-UK can provide a reference to standardize the clinical application of rhPro-UK and promote its rational use.
